Image

Effectiveness of a Digital Health Application for Subacute and Chronic Back Pain (Relevis)

Effectiveness of a Digital Health Application for Subacute and Chronic Back Pain (Relevis)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This clinical trial with 276 patients with subacute or chronic back pain aims to investigate the effectiveness of the unguided digital therapeutic relevis for patients with subacute or chronic back pain. Inclusion criteria are: age ≥ 18 years, presence of subacute (6-12 weeks) or chronic (>12 weeks) back pain, attested by a medical certificate (relevant ICD-10-GM diagnoses: M47.8x, M47.9x, M54.5, M54.8x, M54.9x, M51.0x, M51.1x, M51.2), impaired functional ability [Oswestry Disability Index (ODI) ≥ 21], consent to participation, sufficient knowledge of the German language. Exclusion criteria are: change in treatment of back pain in the past month, planned change in treatment of back pain in the next 3 months, prior use of other online programs/apps for back pain, history of back, hip or knee surgery in the past 6 months, history of more than one back surgery in lifetime, presence of a specific cause for back pain (e.g., fracture, infection, neuropathies [except when due to disc prolapse], axial spondyloarthritis), tumor or metastases, cauda equina syndrome, acute myocardial infarction, unstable coronary heart disease/angina pectoris or heart failure, acute thrombosis, manifest osteoporosis, acute fevers, rheumatic autoimmune diseases.

Patients will be randomized and allocated to either an intervention group in a 1:1 ratio, in which they will receive access to relevis in addition to treatment as usual (TAU, n = 138), or to a control group, in which they will receive only TAU (n = 138). TAU is defined as any therapy prescribed or recommended by the GP or specialists (e. g. orthopedic surgeon, rheumatologists etc.) which may include physiotherapy, injections in the spine, drug therapy, orthesis, etc. (1,2). The primary endpoint will be the functional impairment, measured by the ODI, with three months post-allocation being the primary time point for assessment of effectiveness (T1). Six months post-allocation (T2) will be used as the follow-up assessment endpoint. Secondary endpoints will be depression, work and social functioning, pain intensity, and health-related quality of life.

Eligibility

Inclusion Criteria:

  • Age ≥ 18
  • Presence of subacute (6-12 weeks) or chronic (>12 weeks) back pain
  • Submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of back pain:
    • M47.8x - Spondylosis
    • M47.9x - Other spondylosis
    • M54.5 - Back pain
    • M54.8x - Other back pain
    • M54.9x - Unspecified back pain
    • M51.0x - Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with myelopathy
    • M51.1x - Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathy
    • M51.2 - Other thoracic, thoracolumbar and lumbosacral intervertebral disc displacement
  • Impaired functional ability (ODI ≥ 21)
  • Consent to participate
  • Sufficient knowledge of the German language

Exclusion Criteria:

  • Change in treatment of back pain in the past month
  • Planned change in treatment of back pain in the next 3 months
  • Prior use of other online programs/apps for back pain
  • History of back, knee or hip surgery in the past 6 months
  • History of more than one back surgery during lifetime
  • Presence of a specific cause for back pain, e.g.:
    • Fracture
    • Infection
    • Neuropathies (except when due to disc prolapse)
    • Axial spondyloarthritis
  • Tumor or metastases
  • Cauda equina syndrome
  • Acute myocardial infarction
  • Unstable coronary heart disease/angina pectoris or heart failure
  • Acute thrombosis
  • Manifest osteoporosis
  • Acute fevers
  • Rheumatic autoimmune diseases

Study details
    Back Pain

NCT06221956

Gaia AG

15 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.